SCHEMBL4153687

SCHEMBL4153687

FC(F)(F)c1ccc2[nH]c3c(c2c1)CCCC3Nc1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.56
ALOX15 P16050 3/20 0.55
MAPT P10636 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
GLA P06280 1/20 0.55
MAPK1 P28482 1/20 0.53
DHODH Q02127 1/20 0.46
SIRT1 Q96EB6 7/20 0.46
BRD3 Q15059 4/20 0.45
SIRT2 Q8IXJ6 3/20 0.45
SIRT3 Q9NTG7 2/20 0.45
GAA P10253 1/20 0.43
CASP6 P55212 1/20 0.43
TSHR P16473 1/20 0.41
TRPA1 O75762 1/20 0.41
CDC42 P60953 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4157241 0.94 ALOX15 (0.59) CYP2D6ALOX15MAPTSMN1; SMN2MEN1
SCHEMBL4165012 0.93 CYP2D6 (0.61) CYP2D6ALOX15MAPTSMN1; SMN2MEN1
SCHEMBL4158164 0.90 CYP2D6 (0.70) CYP2D6ALOX15MAPTSMN1; SMN2MEN1
Hydrochloric Acid SCHEMBL4150220 0.89 CYP2D6 (0.69) CYP2D6ALOX15MAPTSMN1; SMN2MEN1
SCHEMBL16433491 0.89 CYP2D6 (0.56) CYP2D6ALOX15MAPTSMN1; SMN2MEN1
SCHEMBL16433490 0.89 CYP2D6 (0.56) CYP2D6ALOX15MAPTSMN1; SMN2MEN1
SCHEMBL4148681 0.88 ALOX15 (0.68) CYP2D6ALOX15MAPTSMN1; SMN2MEN1
SCHEMBL16433488 0.88 ALOX15 (0.58) CYP2D6ALOX15MAPTSMN1; SMN2MEN1
SCHEMBL4155508 0.86 CYP2D6 (0.53) CYP2D6ALOX15MAPTSMN1; SMN2MEN1
SCHEMBL4151891 0.86 CYP2D6 (0.74) CYP2D6ALOX15MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
EP-1817025-A2 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC Therapeutics, Inc. (US) 2007-08-15 EP disclosed
WO-2006065480-A2 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control VEGFA, FLT4, KDR CYP2D6 4677/4885ALOX15 1442/4885MAPT 2774/4885
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL VEGFA, FLT4, KDR CYP2D6 4677/4885ALOX15 1442/4885MAPT 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.